NCT04160455: ATGALIG-HIV

Study of Autophagy and the Effects of GALIG Gene Products in HIV-1 Infected Patients Who Are Under Antiretroviral Therapy Since Primary-infection, Chronic Phase, or Never Treated.

Recruiting now Last updated 30 December 2025

What this trial tests

trial testing expression of a panel in Autophagy in 180 participants. Currently enrolling.

Timeline

7 November 2019

Primary endpoint
7 November 2029

7 November 2039

Quick facts

Lead sponsor	Centre Hospitalier Régional d'Orléans
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	180
Start date	7 November 2019
Primary completion	7 November 2029
Estimated completion	7 November 2039
Sites	1 location across France

Drugs / interventions tested

• expression of a panel — full drug profile →

Conditions studied

• Autophagy — all drugs for Autophagy →
• Galectins — all drugs for Galectins →
• HIV Infections — all drugs for HIV Infections →
• Highly Active Antiretroviral Therapy — all drugs for Highly Active Antiretroviral Therapy →

Sponsor

Centre Hospitalier Régional d'Orléans

Who can join

18 and older, any sex, with Autophagy or Galectins. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Little is known about autophagy during HIV infection. Recently, two different teams reported important dysfunctions of autophagy in HIV-infected patients despite sustained suppressive antiretroviral therapy. As altered autophagy is strongly linked to cellular senescence and chronic inflammation, two hallmarks of HIV-infected patients despite long-term suppressive antiretroviral therapy, it is important to improve our knowledge in the area.

Our main objective is to determine whether all or part of mononuclear cell subpopulations (CD4+ and CD8+ T lymphocytes, and monocytes) exhibit a defect in autophagy function in a cohort of HIV-infected patients who are virologically-controlled (plasma HIV RNA \<50 copies / ml) either spontaneously (i.e. HIV controllers or post-treatment controllers) or after they started antiretroviral therapy at different time points (i.e. at the acute or chronic phases), as compared with a control group (i.e. uninfected healthy blood donors).

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

1. Autophagy and Autophagy-Related Diseases: A Review.
   Ichimiya T, Yamakawa T, Hirano T, Yokoyama Y, et al · · 2020 · cited 240× · PMID 33255983 · DOI 10.3390/ijms21238974
2. Multiple Facets of Autophagy and the Emerging Role of Alkylphosphocholines as Autophagy Modulators.
   Kaleağasıoğlu F, Ali DM, Berger MR. · · 2020 · cited 26× · PMID 32410999 · DOI 10.3389/fphar.2020.00547
3. The Fragile Balance: Autophagy's Role in Neurodegenerative Disease Progression.
   Bhushan B, Dhanawat M, Garima, Wilson K, et al · · 2026 · PMID 40619658 · DOI 10.2174/011570159x377552250627113915